NovalGen Ltd of the UK has announced a number of key appointments to its management team as it prepares to bring its first bispecific antibody therapeutic into human trials. The company’s founder, Amit Nathwani, a professor at University College London, becomes chief executive and member of the board of directors. Prof Nathwani is an entrepreneur in cancer research, immunology and gene therapy. He is also the founder of Freeline Therapeutics Ltd, where he remains on the board.
Among the five other new members of the executive team joining Prof Nathwani at NovalGen, are his fellow UCL professor, Kerry Chester, who becomes chief scientific officer, and Natalia Misciattelli, who joins as chief business officer.
NovalGen announced the appointments on 19 February 2021
Copyright 2021 Evernow Publishing Ltd